Pre-made Navicixizumab benchmark antibody ( Bispecific mAb, anti-DLL4;VEGFA therapeutic antibody, Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-369

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-369 Category Tags ,

Product Details

Pre-Made Navicixizumab biosimilar, Bispecific mAb, Anti-DLL4;VEGFA Antibody: Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Navicixizumab is an anti-DLL4/VEGF bispecific antibody that has demonstrated robust in vivo antitumor efficacy in a number of solid tumor xenografts. In the phase Ia trial of the monotherapy, 66 patients with various solid tumors were treated once every 3 weeks in 1 of 8 dose-escalation cohorts or an expansion cohort.

Products Name (INN Index)

Pre-Made Navicixizumab biosimilar, Bispecific mAb, Anti-DLL4;VEGFA Antibody: Anti-AOS6/delta4/hdelta2;VPF/VEGF/MVCD1 therapeutic antibody

INN Name

Navicixizumab

Target

DLL4,VEGFA

Format

Bispecific mAb

Derivation

Bispecific antibody

Species Reactivity

Human

CH1 Isotype

IgG2

VD LC

Kappa,Kappa

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Active

100% SI Structure

None;None

99% SI Structure

None;None

95-98% SI Structure

None;None

Year Proposed

2015

Companies

OncoMed Pharmaceuticals

Conditions Approved

NA

Conditions Active

Fallopian tube cancer,Ovarian cancer,Peritoneal cancer

Conditions Discontinued

Colorectal cancer,Solid tumours

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

DLL4,VEGFA

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide